|
As
of September 30, 2022, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive (all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022):
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from common stock options |
|
|
177,815 |
|
| Shares from common stock warrants |
|
|
242,639 |
|
| Shares from the conversion of convertible notes and accrued interest |
|
|
79,727 |
|
| Shares from the conversion of Series A Stock inclusive of cumulative dividends |
|
|
111,563 |
|
| Shares from the conversion of Series B Preferred Stock inclusive of dividends |
|
|
271,490 |
|
| |
|
|
883,234 |
|
As
of September 30, 2021, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive (all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022):
| Shares from common stock options |
|
|
27,815 |
|
| Shares from common stock warrants |
|
|
188,892 |
|
| Shares from the conversion of debentures |
|
|
5,469 |
|
| Shares from the conversion of Series A Stock |
|
|
107,172 |
|
| Shares from the conversion of Series B Preferred Stock |
|
|
235,781 |
|
| Shares from the conversion of Series E-1 Preferred Stock |
|
|
212,500 |
|
| |
|
|
777,629 |
|
|